Goldman Sachs Group Inc Arcutis Biotherapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,589,882 shares of ARQT stock, worth $22.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,589,882
Previous 807,334 96.93%
Holding current value
$22.4 Million
Previous $7.51 Million 96.92%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$8.32 - $11.0 $6.51 Million - $8.61 Million
782,548 Added 96.93%
1,589,882 $14.8 Million
Q2 2024

Aug 13, 2024
BUY
$7.24 - $12.53 $5,864 - $10,149
810 Added 0.1%
807,334 $7.51 Million
Q1 2024

May 15, 2024
BUY
$3.25 - $11.77 $238,946 - $865,353
73,522 Added 10.03%
806,524 $7.99 Million
Q4 2023

Feb 13, 2024
BUY
$1.84 - $4.82 $735,985 - $1.93 Million
399,992 Added 120.11%
733,002 $2.37 Million
Q3 2023

May 14, 2024
SELL
$5.31 - $10.98 $2.12 Million - $4.39 Million
-399,992 Reduced 54.57%
333,010 $1.77 Million
Q3 2023

Nov 14, 2023
SELL
$5.31 - $10.98 $1.92 Million - $3.97 Million
-361,311 Reduced 52.04%
333,010 $1.77 Million
Q2 2023

May 14, 2024
BUY
$7.51 - $15.0 $3.36 Million - $6.71 Million
447,345 Added 181.13%
694,321 $6.62 Million
Q2 2023

Aug 14, 2023
BUY
$7.51 - $15.0 $3.36 Million - $6.71 Million
447,345 Added 181.13%
694,321 $6.62 Million
Q1 2023

May 14, 2024
SELL
$10.23 - $17.14 $334,408 - $560,289
-32,689 Reduced 11.69%
246,976 $2.72 Million
Q1 2023

May 11, 2023
SELL
$10.23 - $17.14 $334,408 - $560,289
-32,689 Reduced 11.69%
246,976 $2.72 Million
Q4 2022

May 14, 2024
BUY
$13.96 - $20.4 $1.35 Million - $1.97 Million
96,368 Added 52.57%
279,665 $4.14 Million
Q4 2022

Feb 13, 2023
BUY
$13.96 - $20.4 $1.35 Million - $1.97 Million
96,368 Added 52.57%
279,665 $4.14 Million
Q3 2022

May 14, 2024
BUY
$17.85 - $26.95 $1.56 Million - $2.35 Million
87,119 Added 90.58%
183,297 $3.5 Million
Q3 2022

Nov 10, 2022
BUY
$17.85 - $26.95 $1.56 Million - $2.35 Million
87,119 Added 90.58%
183,297 $3.5 Million
Q2 2022

May 14, 2024
SELL
$16.33 - $22.2 $10.4 Million - $14.1 Million
-636,824 Reduced 86.88%
96,178 $2.05 Million
Q2 2022

Aug 15, 2022
BUY
$16.33 - $22.2 $548,769 - $746,031
33,605 Added 53.71%
96,178 $2.05 Million
Q1 2022

May 16, 2022
BUY
$14.38 - $22.79 $206,194 - $326,785
14,339 Added 29.73%
62,573 $1.21 Million
Q4 2021

Feb 14, 2022
BUY
$14.98 - $25.5 $113,952 - $193,978
7,607 Added 18.72%
48,234 $1 Million
Q3 2021

Nov 10, 2021
BUY
$19.28 - $27.1 $783,288 - $1.1 Million
40,627 New
40,627 $971,000

Others Institutions Holding ARQT

# of Institutions
197
Shares Held
129M
Call Options Held
738K
Put Options Held
82K
View Full List

About Arcutis Biotherapeutics, Inc.

ARQT Quotes by TradingView
  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $849M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email